E Anaissie

Summary

Country: USA

Publications

  1. ncbi request reprint Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years
    A Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Br J Haematol 114:600-7. 2001
  2. ncbi request reprint Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
    M Zangari
    Central Arkansas Veterans Healthcare System and the University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Blood 98:1614-5. 2001
  3. ncbi request reprint Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone
    K R Desikan
    The Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 112:242-7. 2001
  4. ncbi request reprint Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
    B Barlogie
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 98:492-4. 2001
  5. ncbi request reprint Transplantation as salvage therapy for high-risk patients with myeloma in relapse
    C K Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Bone Marrow Transplant 30:873-8. 2002
  6. ncbi request reprint Results of autologous stem cell transplant in multiple myeloma patients with renal failure
    A Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Br J Haematol 114:822-9. 2001
  7. ncbi request reprint Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant
    C K Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, 72205, USA
    Bone Marrow Transplant 33:823-8. 2004
  8. ncbi request reprint High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions
    A Badros
    Myeloma and Transplantation Research Center and Department of Pathology, University of Arkansas for Medical Sciences and Veterans Health System, Little Rock, USA
    Blood 97:2574-9. 2001
  9. ncbi request reprint Thalidomide in the management of multiple myeloma
    B Barlogie
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Semin Hematol 38:250-9. 2001
  10. ncbi request reprint Clinical activity of arsenic trioxide for the treatment of multiple myeloma
    N C Munshi
    University of Arkansas for Medical Sciences, Myeloma and Transplantation Medical Center, Little Rock, AR, USA
    Leukemia 16:1835-7. 2002

Collaborators

Detail Information

Publications16

  1. ncbi request reprint Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years
    A Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Br J Haematol 114:600-7. 2001
    ..In conclusion, MEL-140 is less toxic and appears equally as efficacious as MEL-200 in elderly patients. The benefits of tandem SCT in this patient population need further evaluation in a randomized trial...
  2. ncbi request reprint Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
    M Zangari
    Central Arkansas Veterans Healthcare System and the University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Blood 98:1614-5. 2001
    ....
  3. ncbi request reprint Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone
    K R Desikan
    The Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 112:242-7. 2001
    ..e. beta(2)-microglobulin levels > 2.5 mg/l, probably benefit from chemotherapy for mobilization both in terms of cytoreduction and adequate stem cell mobilization resulting in accelerated engraftment...
  4. ncbi request reprint Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
    B Barlogie
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 98:492-4. 2001
    ..Response rates were higher and survival was longer especially in high-risk patients given more than 42 g THAL in 3 months (median cumulative dose) (landmark analysis); this supports a THAL dose-response effect in advanced MM...
  5. ncbi request reprint Transplantation as salvage therapy for high-risk patients with myeloma in relapse
    C K Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Bone Marrow Transplant 30:873-8. 2002
    ..001). Their survival at 2 years post-ST was 43%, 17% and 11%, respectively. Our study suggests further transplantation should only be considered in the setting of a clinical trial in patients with favorable prognostic factors...
  6. ncbi request reprint Results of autologous stem cell transplant in multiple myeloma patients with renal failure
    A Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Br J Haematol 114:822-9. 2001
    ..MEL-140 had an acceptable toxicity and appeared equally effective as MEL-200. In the setting of renal failure, the role of auto-SCT early in the disease course and benefits of tandem SCT require further evaluation...
  7. ncbi request reprint Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant
    C K Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, 72205, USA
    Bone Marrow Transplant 33:823-8. 2004
    ..05). Our data suggest that significant renal failure can be reversible and AT should be considered early in the disease course...
  8. ncbi request reprint High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions
    A Badros
    Myeloma and Transplantation Research Center and Department of Pathology, University of Arkansas for Medical Sciences and Veterans Health System, Little Rock, USA
    Blood 97:2574-9. 2001
    ..Remarkable graft versus myeloma responses were seen in chemotherapy-refractory patients. Two patients died of progressive disease, and 3 died of GVHD complications without active disease. GVHD remains a major problem with this procedure...
  9. ncbi request reprint Thalidomide in the management of multiple myeloma
    B Barlogie
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Semin Hematol 38:250-9. 2001
    ..The virtual lack of myelosuppression makes it an ideal agent for combination with cytotoxic chemotherapy. Newer, more potent, and less toxic derivatives of thalidomide are being evaluated...
  10. ncbi request reprint Clinical activity of arsenic trioxide for the treatment of multiple myeloma
    N C Munshi
    University of Arkansas for Medical Sciences, Myeloma and Transplantation Medical Center, Little Rock, AR, USA
    Leukemia 16:1835-7. 2002
    ..The results of this small trial support further investigation of this novel drug for the treatment of patients with relapsed or refractory MM...
  11. pmc VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma
    M Pineda-Roman
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Leukemia 22:1419-27. 2008
    ..The MMSET/FGFR3 molecular subtype was prognostically favorable, a finding since reported for a VTD-incorporating tandem transplant trial (Total Therapy 3) for untreated patients with myeloma (BJH 2008)...
  12. ncbi request reprint Thalidomide in the management of multiple myeloma
    B Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205, USA
    Semin Oncol 28:577-82. 2001
    ..Several trials are currently underway at the Arkansas Myeloma and Transplantation Research Center to determine the clinical benefit of adding thalidomide to post-transplant salvage therapy and in the upfront management of patients...
  13. ncbi request reprint Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications
    M Zangari
    Central Arkansas Veteran s Healthcare System, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Blood Coagul Fibrinolysis 13:187-92. 2002
    ..In conclusion, in this series, acquired APC resistance was present in almost one-quarter of newly diagnosed myeloma patients and significantly increased the risk of DVT...
  14. pmc Suppression of abnormal karyotype predicts superior survival in multiple myeloma
    V Arzoumanian
    Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Leukemia 22:850-5. 2008
    ..35, P=0.044) and relapse (HR=2.47, P<0.001). Collectively, these results underscore the importance of monitoring for CA and attest to the favorable prognostic consequences of CA suppression with effective therapy...
  15. ncbi request reprint 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes
    T Mahfouz
    University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock, 72205, USA
    J Clin Oncol 23:7857-63. 2005
    ..To determine the role of FDG-PET in the diagnosis of infection in patients with multiple myeloma (MM)...
  16. ncbi request reprint Serial measurement of serum C-reactive protein levels can identify patients at risk for severe complications following autologous stem cell transplantation
    A B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Leuk Lymphoma 46:1159-61. 2005
    ..A cut-off point of 100 mg/l (CRP levels) and 15 mg/l/day (CRP velocity) identified patients likely to suffer severe complications with 86 and 75% sensitivity, respectively. Prospective validation of this model is currently underway...